Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 11th 2016

Shaping the Future of Immuno-Oncology

Joseph Alvarnas, MD

While the number and diversity of immunologically-based anticancer agents have increased dramatically, a number of challenging questions persist: sequencing with existing regimens, selection of best responders, cost, and patient access.

February 11th 2016

Study Compares Filgrastim vs Tbo-Filgrastim in Patients With Myeloma

Priyam Vora

While there are no significant differences in the results between filgrastim and tbo-filgrastim in a clinical setting, tbo-filgrastim offers significant cost savings over filgrastim.

February 10th 2016

New Device, With Localized Drug Delivery to Pancreatic Tumors, Could Reduce AE

Surabhi Dangi-Garimella, PhD

Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.

February 10th 2016

Patient Assistance: Implementing Preventative Steps to Ensure Financial Wellness

Jacqueline Cab&aacute n Charles Lynch

An overview of patient assistance programs at Smilow Cancer Hospital at Yale-New Haven, including their innovative hospital-based explanation of benefits form, which can eliminate patient responsibilities and help expedite the turnaround times for payment processing with copay assistance.

February 10th 2016

Patient Access to Immuno-Oncology Agents - A US Policy Perspective

Surabhi Dangi-Garimella, PhD

The cost issues with immuno-oncology agents are real, but so is the value that they bring to the table. How can we improve access to these agents at a reasonable cost?

February 10th 2016

Study Hopes to Resolve Questions About Management of Pre-Cancers of the Breast

Jackie Syrop

As physicians and researchers question whether certain treatments for early signs of breast cancer are necessary, the first large US study will seek to determine the best way to manage ductal carcinoma in situ.

February 9th 2016

Strong Gains for Healthcare and Research in President Obama's 2017 Budget

Surabhi Dangi-Garimella, PhD

Innovation has remained high on the administration’s agenda, as is evident from the allocations to tackle climate changes as well as find treatments for devastating health conditions.

February 9th 2016

Access to Immuno-Oncology Therapies - European Policy Perspective

Suzanne Wait, PhD

Ensuring rapid, appropriate, and sustainable access to immuno-oncology therapies for patients in Europe: what role can policies play?

February 8th 2016

ASCO Recommends Biomarker Use to Guide Early Breast Cancer Therapy Decisions

Surabhi Dangi-Garimella, PhD

The panel members that have proposed the recommendations have found clinical utility for several genomic tests to guide clinical decision in women with early stage breast cancer.

February 8th 2016

PhRMA Plans Targeted Ad Campaign in Wake of Focus on Drug Costs

Mary Caffrey

The ads will be targeted at about 7000 "influencers" including lawmakers who could control whether drug prices are regulated. Many have called for Medicare to gain the right to negotiate drug prices.

February 8th 2016

Evolving Practices in Managing Costly Immunotherapy

Carina Verdier Dolan, PharmD, BCOP

To address the nationwide concern of costly immunotherapy agents, this article features health system inpatient and outpatient strategies that can help mitigate their costs.

February 8th 2016

PCPs Diligent With Following USPSTF Recommendations on PSA Testing

Surabhi Dangi-Garimella, PhD

Using data gathered from the National Ambulatory Medical Care Survey, the authors of a JAMA Internal Medicine study identified a significant decrease in PSA testing referrals by primary care physicians compared with urologists.

February 7th 2016

What We Know About California's Right-to-Die Law, Except When It Takes Effect

Mary Caffrey

A quirk in California law means the law that Governor Jerry Brown signed with much fanfare last fall hasn't taken effect yet, even though its passage is having ripple effects.

February 7th 2016

Considering the Burden on Family Caregivers

Priyam Vora

A deeper understanding of the interdependencies among the patients, family caregivers, and service providers revealed that if general practice teams intervene early, they may be more likely meet patients’ needs in the end-of-life care process.

February 6th 2016

Lipegfilgrastim a Possible Alternative for Managing Chemotherapy-Induced Neutropenia

Jessica Men

The novel molecule lipegfilgrastim has been shown to be relatively equivalent to pegfilgrastim in the management of chemotherapy-induced neutropenia among patients with breast cancer.

February 5th 2016

AJMC Staff

Scientists at the FDA have provided their recommendation to be submitted to an independent medical advisory panel that will decide the fate of Remsima.

February 5th 2016

Cancer Treatment Financially Devastating in Young Adult Survivors, Says Samfund Study

Surabhi Dangi-Garimella, PhD

The paper in Cancer Medicine finds that cancer has a devastating and age-specific impact on the finances of young adult survivors.

February 5th 2016

Where Does Immuno-Oncology Fit in a Value-Based Care Delivery Model?

Bruce Feinberg, DO

Advances made in the field of immuno-oncology (I-O) in 2015 have greatly expanded our understanding of I-O and added more complexity to its value assessment.

February 5th 2016

The Fight of Our Lives: Confronting the Unmet Need in Lung Cancer

Bonnie J. Addario

Supporting, funding, and protecting the research and development of new medicines and new treatments is more critical, now than ever, to provide better treatments and better outcomes to all cancer patients.

February 4th 2016

High Risks, High Costs Associated With Febrile Neutropenia in Metastatic Cancer

Jackie Syrop

Data from 2 large studies of patients with metastatic disease who underwent myelosuppressive chemotherapy found that febrile neutropenia occurred in approximately 13% to 21% of patients. Associated costs of febrile neutropenia were found to range from $16,000 to $19,000 per episode for most hospitalized patients.

February 4th 2016

ASCO Highlights the Year in Oncology Advances

Laura Joszt, MA

The annual Clinical Cancer Advances report from the American Society of Clinical Oncology highlights the accomplishments made in the last year in the fight against cancer.

February 4th 2016

On World Cancer Day, Stories of Courage and Support

Surabhi Dangi-Garimella, PhD

On World Cancer Day, The American Journal of Managed Care would like to acknowledge the determination of cancer survivors and the support provided by various organizations to patients and their families.

February 4th 2016

Immuno-Oncology 2016 and Beyond: The Opportunities, Challenges, and Risks

Michael V. Seiden, MD, PhD

The translation of immuno-oncology agents from the research to the practice arena may provide significant clinical benefit to patients with difficult-to-treat malignancies. The further development and marketing of these agents could escalate the discussion on care equity in a time of constrained resources.

February 3rd 2016

Fight With or Adapt to Rising Drug Prices? Economists Debate at the AcademyHealth Conference

Surabhi Dangi-Garimella, PhD

Rising drug prices, the effect on the healthcare system, consumer push-back, and possible solutions were debated by the expert panel.

February 3rd 2016

Molecular Testing Patterns in Metastatic Non—Small Cell Lung Cancer

Elizabeth MacLean, PharmD Anthony Louder, PhD, RPh Kim Saverno, PhD, RPh Gregory Smith, BA Jack Mardekian, PhD Cari Bruins, PharmD Melea Ward, PharmD, PhD Robert Sweetman, MD Margaret Pasquale, PhD

Assessment of the timing of histologic and molecular testing indicates that testing occurred prior to treatment initiation for most patients with metastatic nonâ€”small cell lung cancer.

February 2nd 2016

Rationing Care in Times of Drug Shortages

Surabhi Dangi-Garimella, PhD

Pediatric oncologists from across the country covened a task force to develop an ethical framework that guides decisions on allocation based on curability, prognosis, and the incremental importance of a drug to a patient’s outcome

February 2nd 2016

Comparing End-of-Life Care for Cancer Patients in 7 Developed Countries

Priyam Vora

Among 7 developed countries, the United States has the lowest proportion of deaths that occur in the hospital and the lowest number of days spent in the hospital during the last 6 months of life.

February 1st 2016

How Successful Will Gleevec's Generic Competitor Be?

Surabhi Dangi-Garimella, PhD

The generic manufacturer may try to maximize profits during the initial exclusivity period, says an expert from a leading health plan.

February 1st 2016

Will New Evidence for Proton Radiotherapy Swing Payers?

Surabhi Dangi-Garimella, PhD

With increasing evidence of comparable efficacy and reduced toxicity of proton beam therapy, payers may have to reevaluate coverage policies.

February 1st 2016

What We're Reading: Cancer Moonshot Creates Hard Feelings With Some Researchers

AJMC Staff

What we're reading, February 1, 2016: some medical researchers disagree with sharing raw data used in their research; the medical community is torn on whether or not the annual checkup is worthwhile; and Donald Trump vows to extend healthcare coverage to the lower class.

...

111 112 113 114 115 116 117 118 119

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions